Preview

Лечащий Врач

Расширенный поиск

Возможности нефропротекции у коморбидного больного артериальной гипертензией

Полный текст:

Аннотация

Рассмотрено применение гипотензивных препаратов в повседневном ведении коморбидных больных артериальной гипертензией. Уделено внимание профилю нефропротекции современных гипотензивых препаратов, знание о котором необходимо терапевтам и врачам общей практики.

Об авторах

А. С. Скотников
ФГАОУ ВО Первый МГМУ им. И. М. Сеченова МЗ РФ
Россия


А. Э. Никитин
ФГБУЗ ЦКБ РАН
Россия


С. С. Сименюра
АНО НИЦ «Рациональная медицина»
Россия


Список литературы

1. Tonelli M., Wiebe N., Culleton B., House A., Rabbat C., Fok M., McAlister F., Garg A.?X. Chronic Kidney Disease and Mortality Risk: A Systematic Review // Am Soc Nephrol. 2006; 17: 2034–2047.

2. VanBiesen W., Vanholder R., Lameire N. Dialysis strategies in critically ill acute renal failure patients // CurrOpinCritCare. 2003; 9: 491–495.

3. Klag M.?J., Whelton P.?K., Randall B.?L., Neaton J.?D., Brancati F.?L., Ford C.?E., Shulman N.?B., Stamler J. Blood pressure and end-stage renal disease in men // N Engl J Med. 1996, Jan 4; 334 (1): 13–18.

4. Onuigbo M.?A., Onuigbo N.?T. Late-onset renal failure from angiotensin blockade (LORFFAB) in 100 CKD patients // Int. Urol. Nephrol. 2008. Vol. 40. P. 233–239.

5. Rahman M., Pressel S., Davis B.?R. Renal outcomes in high-risk hypertensive patients treated with ACEI or calcium channel blocker versus diuretics: a report of ALLHAT trial // Arch Int Med. 2005, 165: 936–946.

6. Marre M., Fernandez M., Garsia-Puig J. Value of natrilix SR in hypertensive type 2 diabetic patients with microalbuminuria // J.?Hypertens. Res. 2002, 20 (Suppl. 4): 338–342.

7. Adler A., Stratton I. M., Neil H. Assoсiation of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study // BMJ. 2000; 321: 4129.

8. Maschio G., Alberti D., Janin G. et al. Effect of the angiotensinconverting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group // N.?Engl. J.?Med. 1996; 334 (15): 939–945.

9. Bakris G.?L., Sarafidis P.?A., Weir M.?R., Dahl?f B., Pitt B., Jamerson K., Velazquez E.?J., Staikos-Byrne L., Kelly R.?Y., Shi V., Chiang Y.-T., Weber M.?A. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial // Lancet. 2010; 375 (9721): 1173–1181.

10. The GISEN Group. Randomised placebo controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy // Lancet. 1997; 349: 1857–1863.

11. Agodoa L.?Y., Appel L., Bakris G.?L. African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial // JAMA. 2001; 285 (21): 2719–2728.

12. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO–HOPE substudy // Lancet. 2000. Vol. 355. Р. 253–259.

13. Marre M., Lievre M., Chatellier G. et al. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study) // BMJ. 2004; 328 (7438): 495.

14. O’Hare P., Bilbous R., Mitchell T. et al. Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension. The ATLANTIS study group // Diabetes Care. 2000; 23 (12): 1823–1829.

15. Herlitz H., Harris K., Risler T., Boner G., Bernheim J., Chanard J., Aurell M. The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros Study // Nephrol Dial Transplant. 2001, Nov; 16 (11): 2158–2165.

16. The EUCLID study group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria // Lancet. 1997; 349: 1787–1792.

17. Goa K.?L., Hatua M., Wilde M.?I. Lisinopril. A review of its pharmacology and use in the management of the complications of diabetes mellitus // Drugs. 1997; 53 (6): 1081–1105.

18. Estacio R.?O., Jeffers B.?W., Hiatt W.?R. et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension // N Engl J Med. 1998, Mar 5; 338: 645–652.

19. Lewis E.?J., Hunsicker L., Вain R. et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy // N.?Engl. J.?Med. 1993. Vol. 329,1456–1462.

20. Ruggenenti P., Fassi A., Ilieva A.?P., Bruno S., Iliev I. P., Brusegan V., Rubis N., Gherardi G., Arnoldi F., Ganeva M., Ene-Iordache B., Gaspari F., Perna A., Bossi A., Trevisan R., Dodesini A.?R., Remuzzi G. Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes // N Engl J Med. 2004, Nov 4; 351 (19): 1941–1951.

21. Marin R., Ruilope L.?M., Aljama P., Aranda P., Segura J., Diez J. Investigators of the ESPIRAL Study. Efecto del tratamiento antihipertensivo Sobre la Progresi?n de la Insuficiencia RenAL en pacientes no diab?ticos. A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease // J Hypertens. 2001, Oct; 19 (10): 1871–1876.

22. Ruilope L., Segura J. Renal protection in diabetic patients: benefits of first-line combination of perindopril-indapamide // J Hypertens. 2006; 24 (3): 9–12.

23. Mogensen C., Viberti G., Halimi S. et al. Effect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER // Hypertension. 2003, 41, 1063–1071.

24. Dahlof B., Gosse P., Gueret P. Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study // J.?Hypertens. 2005, 23, 2063–2070.

25. Robles N.?R., Ocon J., Gomez C.?F., Manjon M., Pastor L., Herrera J., Villatoro J., Calls J., Torrijos J., Rodr?guez V. I., Rodriguez M.?M. A., Mendez M.?L., Morey A., Martinez F.?I., Marco J., Liebana A., Rincon B., Tornero F. Lercanidipine in patients with chronic renal failure: the ZAFRA study // Ren. Fail. 2005; 27 (1): 73–80.

26. Marre M., Puig J.?G., Kokot F. еt al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR study // J.?Hypertens. 2004; 22: 1613–1622.

27. Lewis E.?J., Hunsicker L.?G., Clarke W.?R. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes // N Engl J Med. 2001; 345: 851–860.

28. Parving H.?H., Lehnert H., Brochner-Mortensen J. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes // N Engl J Med. 2001; 345: 870–878.

29. Barnett A.?H., Bain S.?C., Bouter P. Diabetics exposed to telmisartan and enalapril study group. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy // N.?Engl. J.?Med. 2004; Vol. 351 (19): 1952–1961.

30. Makino H., Haneda M., Babazono T. The telmisartan renoprotective study from incipient nephropathy to overt nephropathy — rationale, study design, treatment plan and baseline characteristics of the incipient to overt: angiotensin ii receptor blocker telmisartan, investigation on type 2 diabetic nephropathy (INNOVATION) Study // J Int Med Res. 2005; 33: 677–686.

31. Bakris G., Burgess E., Weir M. Оn behalf of the AMADEO Study Investigators. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy // Kidney Int. 2008; 74 (3): 364.

32. Galle J., Schwedhelm E., Pinnetti S. VIVALDI investigators. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy // Nephrol Dial Transplant. 2008; 23 (10): 3174–3183.

33. Delles C., Raff U., Mimran A. et al. Effects of telmisartan and ramipril on adiponectin and blood pressure in patients with type 2 diabetes // Am. J.?Hypertens. 2008. Vol. 21. № 12. P. 1330–1336;

34. Brenner B., Cooper M., De Zeeuw D. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy // N Engl J Med. 2001; 345: 861–869.

35. Viberti G., Wheeldon N.?M. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus // Circulation. 2002. Vol. 6. Р. 672–678.

36. Estacio R.?O., Coll J.?R., Tran Z.?V., Schrier R.?W. Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes // Am J Hypertens. 2006?19: 1241–1248.

37. The Shiga Microalbuminuria Reduction Trial (SMART) Group. Reduction of Microalbuminuria in Patients with Type 2 Diabetes // Diabetes Care. 2007. Vol. 30 (6). Р. 1581–1583.

38. Ritz E., Viberti G., Ruilope L. Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study // Diabetologia. 2010; 53 (1): 49–57.


Для цитирования:


Скотников А.С., Никитин А.Э., Сименюра С.С. Возможности нефропротекции у коморбидного больного артериальной гипертензией. Лечащий Врач. 2018;(9):29.

For citation:


Skotnikov A.S., Nikitin A.E., Simenyura S.S. Possibilities of nephroprotection in a comorbid patient with arterial hypertension. Lechaschi Vrach. 2018;(9):29. (In Russ.)

Просмотров: 17


Creative Commons License
Контент доступен под лицензией Attribution-NonCommercial-NoDerivatives 4.0 International.


ISSN 1560-5175 (Print)
ISSN 2687-1181 (Online)